Drug
Ly2784544
Ly2784544: highest development phase Phase 2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| 120 mg LY2784544 NCT01594723 | Phase 2 | Neoplasms, Hematologic |
Latest
No recent events.
Follow Ly2784544 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.